Interleukin-6 in renal disease and therapy

Jones, Simon Arnett ORCID: https://orcid.org/0000-0001-7297-9711, Fraser, Donald James ORCID: https://orcid.org/0000-0003-0102-9342, Fielding, Ceri Alan ORCID: https://orcid.org/0000-0002-5817-3153 and Jones, Gareth Wyn 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30 (4) , pp. 564-574. 10.1093/ndt/gfu233

Preview

PDF - Accepted Post-Print Version Download (651kB) | Preview

Abstract

Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > RC Internal medicine
Publisher:	Oxford University Press
ISSN:	0931-0509
Funders:	Arthritis Research UK
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	July 2014
Last Modified:	22 Nov 2024 13:30
URI:	https://orca.cardiff.ac.uk/id/eprint/78708

Citation Data

Cited 54 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item